Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR000428)
Formula Reactant Monomethyl Auristatin E (MMAE) Product Brentuximab vedotin metabolite M4
Reactant Info Product Info
Metabolic Type Oxidation - N-Demethylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR000433 Brentuximab vedotin Monomethyl Auristatin E (MMAE) Oxidation - Oxidation Brentuximab vedotin [1]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR000425 Monomethyl Auristatin E (MMAE) Brentuximab vedotin metabolite M1 Oxidation - O-Demethylation Brentuximab vedotin [2]
MR000426 Monomethyl Auristatin E (MMAE) Brentuximab vedotin metabolite M2 Hydrolysis - Amide Hydrolysis Brentuximab vedotin [2]
MR000427 Monomethyl Auristatin E (MMAE) Brentuximab vedotin metabolite M3 Oxidation - Oxidation Brentuximab vedotin [2]
MR000429 Monomethyl Auristatin E (MMAE) Brentuximab vedotin metabolite M5 Oxidation - Dehydrogenation Brentuximab vedotin [2]
MR000430 Monomethyl Auristatin E (MMAE) Brentuximab vedotin metabolite M6 Oxidation - Demethylation; Oxidation Brentuximab vedotin [2]
MR000431 Monomethyl Auristatin E (MMAE) Brentuximab vedotin metabolite M7 Unclear Brentuximab vedotin [2]
MR000432 Monomethyl Auristatin E (MMAE) Brentuximab vedotin metabolite M8 Unclear Brentuximab vedotin [2]
References
1 DrugBank(Pharmacology-Metabolism)Brentuximab vedotin
2 CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies J Clin Pharmacol. 2013 Aug;53(8):866-77. doi: 10.1002/jcph.116.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.